Hemophagocytic Lymphohistiocytosis Secondary to Chronic Lymphocytic Leukemia Progression

Jancar, Nina; Gonçalves, Filipa Sousa; Duro, José; Aguiar, Patrício; Correia, Catarina Jacinto

doi:10.7759/cureus.34128

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patient had no clinical signs or symptoms of PRES, nor did they have any focal neurological deficits" [9]. "With the progression of the disease, multiple organ infiltration by the activated T cells and macrophages occurs, ultimately leading to multiple organ damage" [10].…”

Section: Discussionmentioning

confidence: 99%

Hemophagocytic Lymphohistiocytosis Secondary to Chronic Lymphocytic Leukaemia and Multiple Infections Manifested with Quotidian Pyrexia: A Case Report

Jemimah,

Raju,

Hariharan

et al. 2023

IJMPCR

View full text Add to dashboard Cite

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening immune regulatory condition that can cause end-organ damage and death. HLH is clinically characterized by uncontrolled activation of cytotoxic T lymphocytes, natural killer cells, and macrophages that can lead to a cytokine storm. Fever, hepatosplenomegaly, cytopenia, elevated liver enzymes, hypertriglyceridemia, hyperferritinemia, and hemophagocytosis in the bone marrow, spleen, or lymph nodes are the hallmarks of the disease. Its primary (genetic) form is typically observed in pediatric patients whereas its secondary, acquired form is seen in adult patients with an underlying autoimmune, malignant, or infectious disease. Here, we present a case of secondary hemophagocytic lymphohistiocytosis in a 70-year-old male with a history of chronic lymphocytic leukemia, severe prolonged COVID-19, and multiple infections who presented with persistent pyrexia of unknown origin (PUO). Diagnosis and management of HLH in adults are often extrapolated from the pediatric HLH-94 and HLH-2004 protocols. The management includes etoposide-based regimens containing corticosteroids, cyclosporine A, intravenous immunoglobulins (IVIG), intrathecal therapy, and liberal allogeneic stem cell transplant use in higher-risk patients. Due to the diverse clinical manifestations and the presence of numerous diagnostic mimics, the diagnosis of HLH is challenging. Since the prognosis is typically poor, prompt diagnosis and strong treatment are required. Here is a description of how our patient is diagnosed and treated based on the HLH 2004 protocol.

show abstract

Section: Discussionmentioning

confidence: 99%